EGFR
Epidermal growth factor receptor; ErbB-1; HER1
The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.
EGFR Isoform Specific Products
All Product Categories
-
EGFR Inhibitors
(1054)
View all products
-
EGFR Agonists
(4)
View all products
-
EGFR Antagonists
(5)
View all products
-
EGFR Activators
(9)
View all products
-
EGFR Modulators
(7)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(5)
View all products
-
EGFR Degraders
(54)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(20)
View all products
-
ErbB2/HER2 Proteins
(40)
View all products
-
ErbB3/HER3 Proteins
(15)
View all products
-
EGFR Proteins
(47)
View all products
-
ErbB4/HER4 Proteins
(10)
View all products
-
EGFR Related Products (1295)
Related Products (1295)
-
Recombinant Proteins (112)
-
Antibodies (19)
-
EGFR Isoform Comparison
-
IMP-Zn
0 ImagesCat. No.: HY-181923IMP-Zn is a pyrazole-hydrazone Schiff base zinc (II) complex. IMP-Zn exhibits significant antiproliferative activity against human colorectal cancer cells and induces cell cycle arrest. IMP-Zn shows stronger binding affinity than its free ligand IMP towards three cancer-related protein targets: EGFR kinase 1M17, cytochrome P450 3RUK, and CDK inhibitor 6GUE. IMP-Zn can be used in studies related to colorectal cancer.
-
Panitumumab (powder)
0 ImagesCat. No.: HY-P99041BCAS No.: 339177-26-3Synonyms: ABX-EGF (powder)
-
AZ14240475
0 ImagesCat. No.: HY-168876CAS No.: 3101563-06-5
-
NM-02
0 ImagesCat. No.: HY-P991239NM-02 is an antibody targeting HER2 with an EC50 value of 1.2 nM. NM-02 binds to domains I and II of HER2-ECD, blocking HER2-related signaling pathways. NM-02 is promising for research of HER2-positive breast cancer.
-
EGFR-IN-80
0 ImagesCat. No.: HY-103437CAS No.: 171745-13-4EGFR-IN-80 (compound 30) is an EGFR inhibitor with a pIC50 of 10.6.
-
HER2-IN-21
0 ImagesCat. No.: HY-172160CAS No.: 906437-59-0HER2-IN-21 (compound 657994) is a human epidermal growth factor receptor 2 (HER2) inhibitor, with an IC50 of 3.85 μM.
-
EGFR-IN-23
0 ImagesCat. No.: HY-142680CAS No.: 2747133-37-3EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC50 of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8).
-
BIEGi-1
0 ImagesCat. No.: HY-17654CAS No.: 1429497-30-2BIEGi-1 is an EGFR inhibitor. BIEGi-1 effectively disrupts the EGFR-Rheb interaction in cells. BIEGi-1 robustly inhibits EGFR kinase activity (reduces p-Y1068-EGFR) as well as mTORC1 activation (reduces p-T389-S6K1) in EGFR-mutant cells. BIEGi-1 shows strong antiproliferative effects on EGFR-mutant PC9 and HCC827 cells with IC50 values of 17 nM and 20 nM, respectively. BIEGi-1 can be used for the study of cancers harboring EGFR mutations, such as non-small cell lung cancer (NSCLC).
-
TX2-120-1
0 ImagesCat. No.: HY-164988CAS No.: 1603845-45-9
-
EGFR-IN-73
0 ImagesCat. No.: HY-151882CAS No.: 2857033-34-0
-
Myristicin (Standard)
0 ImagesMyristicin (Standard) is the analytical standard of Myristicin. This product is intended for research and analytical applications. Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc.
-
GW837016X
0 ImagesCat. No.: HY-129288CAS No.: 833473-68-0Synonyms: NEU-391GW837016X (NEU-391) is an orally active ErbB-2 kinase covalent inhibitor. GW837016X also is a potent antitrypanosome agent. GW837016X inhibits mitosis and cytokinesis.
-
EGFR/COX-2-IN-3
0 ImagesEGFR/COX-2-IN-3 is a selective EGFR/COX-2 dual inhibitor with IC50 values of 0.098 μM and 0.05 μM, respectively. EGFR/COX-2-IN-3 is predicted to have oral activity and blood-brain barrier permeability. EGFR/COX-2-IN-3 exhibits both potent analgesic activity and anti-glioblastoma effects. EGFR/COX-2-IN-3 can be used in the research of tumors such as glioblastoma.
-
DL149
0 ImagesCat. No.: HY-183253DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors.
